XML 32 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Revenue Recognition (Policies)
 3 Months Ended
Mar. 31, 2016
Revenue Recognition [Abstract]  
Revenue Recognition
Concentration of Significant Customers

One distributor and one direct customer comprised 68% of our revenue recognized for the three months ended March 31, 2016.  Two direct customers and one distributor accounted for 68% of total outstanding accounts receivable (excluding receivables from U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA)) as of March 31, 2016.

Three distributors comprised 68% of our revenue recognized for the three months ended March 31, 2015. Two direct customers accounted for 73% of total outstanding accounts receivable as of December 31, 2015.

Product revenues, classified by geographic location, are as follows:

  
Three months ended
 
             
  
March 31, 2016
  
March 31, 2015
 
  
Product
Revenues
  
% of
Total
  
Product
Revenues
  
% of
Total
 
             
Americas
 
$
235,000
   
18
%
 
$
201,000
   
22
%
Japan
  
966,000
   
72
%
  
605,000
   
67
%
EMEA
  
132,000
   
10
%
  
92,000
   
10
%
Asia Pacific
  
—
   
0
%
  
4,000
   
1
%
Total product revenues
 
$
1,333,000
   
100
%
 
$
902,000
   
100
%

Research and Development

We earn revenue for performing tasks under research and development agreements with governmental agencies like the BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues.  Government contract revenue is recorded at the gross amount of the reimbursement.  The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations.   We recognized $1.6 million in BARDA revenue for the three months ended March 31, 2016, as compared to $1.4 million for the three months ended March 31, 2015.